Efficacy of Combination Chemotherapy with Vinorelbine, Ifosfamide, and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer.
- Author:
Heung Moon CHANG
1
;
Jung Ae LEE
;
Jin Seok AHN
;
In Sook WOO
;
Young Iee PARK
;
Jee Woong SON
;
Seung Joon LEE
;
Dong Kyu KIM
;
Eun Kyung MO
;
Myung Jae PARK
;
Myung Goo LEE
;
In Gyu HYUN
;
Ki Suck JUNG
;
Young Suk PARK
Author Information
1. Department of Internal Medicine, Hallym University College of Medicine, Chunchon, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Vinorelbine;
Ifosfamide;
Cisplatin;
Chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Carcinoma, Squamous Cell;
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination*;
Febrile Neutropenia;
Humans;
Ifosfamide*;
Leukopenia
- From:Journal of the Korean Cancer Association
2000;32(3):612-618
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the efficacy and toxicity of combination chemotherapy with vinorelbine, ifosfamide, and cisplatin in patients with advanced non-small cell lung cancer. MATERIALS AND METHODS: Patients with unresectable, pathologically proven non-small cell lung cancer who had no prior chemotherapy were eligible. Patients received vinorelbine (25 mg/m2, iv., D1 & 8), ifosfamide (1.5 g/m2, iv., D1-3 with mesna), and cisplatin (60 mg/m2, iv., D1). The treatment was repeated every 3 weeks. RESULTS: Between degrees Ctober, 1997 and June, 1999, 26 patients were enrolled. Median age was 61. 1 patient had stage IIIA, 13 had stage IIIB, and 12 had stage IV. Patients with adendegrees Carcinoma were 15, squamous cell carcinoma were 11. Of 22 evaluable patients, objective responses were observed in 9 patients (response rate: 40.9%, CR: 1 (4.5%), PR 8 (36.4%)). Median duration of response was 48 weeks. Median overall survival was 52 weeks. Grade 3-4 leukopenia was observed in 10.2% of the 88 courses. There was 1 death related to febrile neutropenia. Non- hematologic toxicities were mild. CONCLUSION: We concluded that combination chemotherapy with vinorelbine, ifosfamide, and cisplatin was effective and tolerable in patients with advanced non-small cell lung cancer, and phase III randomized trial is needed to compare this regimen to other cisplatin-based regimens.
